Advertisement
Singapore markets closed
  • Straits Times Index

    3,338.94
    -9.93 (-0.30%)
     
  • S&P 500

    5,271.54
    -11.86 (-0.22%)
     
  • Dow

    38,522.81
    -48.22 (-0.13%)
     
  • Nasdaq

    16,791.71
    -36.96 (-0.22%)
     
  • Bitcoin USD

    69,373.12
    -478.41 (-0.68%)
     
  • CMC Crypto 200

    1,452.61
    +5.46 (+0.38%)
     
  • FTSE 100

    8,245.67
    -17.08 (-0.21%)
     
  • Gold

    2,354.20
    -15.10 (-0.64%)
     
  • Crude Oil

    73.17
    -1.05 (-1.41%)
     
  • 10-Yr Bond

    4.3530
    -0.0490 (-1.11%)
     
  • Nikkei

    38,837.46
    -85.54 (-0.22%)
     
  • Hang Seng

    18,444.11
    +41.11 (+0.22%)
     
  • FTSE Bursa Malaysia

    1,615.40
    +18.72 (+1.17%)
     
  • Jakarta Composite Index

    7,099.31
    +63.12 (+0.90%)
     
  • PSE Index

    6,386.42
    -84.32 (-1.30%)
     

A Struggling Pfizer Looks for Help From a Wall Streeter

A Struggling Pfizer Looks for Help From a Wall Streeter

As the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a Citi analyst who hasn’t recommended the stock in over a decade. But Andrew Baum has something Pfizer needs: oncology expertise.